| pubmed-article:1561804 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1561804 | lifeskim:mentions | umls-concept:C0025202 | lld:lifeskim |
| pubmed-article:1561804 | lifeskim:mentions | umls-concept:C0021745 | lld:lifeskim |
| pubmed-article:1561804 | lifeskim:mentions | umls-concept:C0027627 | lld:lifeskim |
| pubmed-article:1561804 | lifeskim:mentions | umls-concept:C0025241 | lld:lifeskim |
| pubmed-article:1561804 | lifeskim:mentions | umls-concept:C0444956 | lld:lifeskim |
| pubmed-article:1561804 | lifeskim:mentions | umls-concept:C2003941 | lld:lifeskim |
| pubmed-article:1561804 | lifeskim:mentions | umls-concept:C0031006 | lld:lifeskim |
| pubmed-article:1561804 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:1561804 | lifeskim:mentions | umls-concept:C0332293 | lld:lifeskim |
| pubmed-article:1561804 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:1561804 | pubmed:dateCreated | 1992-5-13 | lld:pubmed |
| pubmed-article:1561804 | pubmed:abstractText | To increase the therapeutic efficacy of recombinant tumor necrosis factor alpha (rTNF alpha) and reduce the systemic side effects, a protocol was designed using isolation perfusion of the limbs with hyperthermia for in transit metastases of melanoma. A triple combination of high dose rTNF alpha + recombinant interferon-gamma (rIFN-gamma) + melphalan was chosen because of a synergistic anti-tumor effect of rTNF alpha with rIFN-gamma and of rTNF alpha with alkylating agents reported in the literature. Twenty-nine patients of mean age 60 years (range 22-82 years) entered the study after informed consent and received a total of 31 isolation perfusions with the triple combination. There were 24 women and 5 men with multiple progressive in transit melanoma metastases of the lower limb (stage IIIa or IIIab). rTNF alpha at the unique dose of 4 mg was injected as a bolus in the arterial line, under mild hyperthermic conditions (40 to 40.5 degrees C) for 90 minutes. rIFN-gamma was given subcutaneously on days -2 and -1 and in the perfusate, with rTNF alpha, at the dose of 0.2 mg. Melphalan was administered in the perfusate at dose giving a concentration of 40 micrograms/ml. In all the 31 isolation perfusions performed in the triple combination protocol, in order to prevent a septic shock-like syndrome which had been encountered in 2 patients treated outside this protocol for sarcoma and carcinoma, the patients received dopamine continuous infusion at 3 micrograms/kg/min from the start of isolation perfusion and for 48 hours, and only showed mild hypotension and very transient chills and temperature.(ABSTRACT TRUNCATED AT 250 WORDS) | lld:pubmed |
| pubmed-article:1561804 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1561804 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1561804 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1561804 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1561804 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1561804 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1561804 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1561804 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1561804 | pubmed:issn | 0364-2313 | lld:pubmed |
| pubmed-article:1561804 | pubmed:author | pubmed-author:LejeuneF JFJ | lld:pubmed |
| pubmed-article:1561804 | pubmed:author | pubmed-author:EwalenkoPP | lld:pubmed |
| pubmed-article:1561804 | pubmed:author | pubmed-author:LiénardDD | lld:pubmed |
| pubmed-article:1561804 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1561804 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:1561804 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1561804 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1561804 | pubmed:pagination | 234-40 | lld:pubmed |
| pubmed-article:1561804 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:1561804 | pubmed:meshHeading | pubmed-meshheading:1561804-... | lld:pubmed |
| pubmed-article:1561804 | pubmed:meshHeading | pubmed-meshheading:1561804-... | lld:pubmed |
| pubmed-article:1561804 | pubmed:meshHeading | pubmed-meshheading:1561804-... | lld:pubmed |
| pubmed-article:1561804 | pubmed:meshHeading | pubmed-meshheading:1561804-... | lld:pubmed |
| pubmed-article:1561804 | pubmed:meshHeading | pubmed-meshheading:1561804-... | lld:pubmed |
| pubmed-article:1561804 | pubmed:meshHeading | pubmed-meshheading:1561804-... | lld:pubmed |
| pubmed-article:1561804 | pubmed:meshHeading | pubmed-meshheading:1561804-... | lld:pubmed |
| pubmed-article:1561804 | pubmed:meshHeading | pubmed-meshheading:1561804-... | lld:pubmed |
| pubmed-article:1561804 | pubmed:meshHeading | pubmed-meshheading:1561804-... | lld:pubmed |
| pubmed-article:1561804 | pubmed:meshHeading | pubmed-meshheading:1561804-... | lld:pubmed |
| pubmed-article:1561804 | pubmed:meshHeading | pubmed-meshheading:1561804-... | lld:pubmed |
| pubmed-article:1561804 | pubmed:meshHeading | pubmed-meshheading:1561804-... | lld:pubmed |
| pubmed-article:1561804 | pubmed:meshHeading | pubmed-meshheading:1561804-... | lld:pubmed |
| pubmed-article:1561804 | pubmed:meshHeading | pubmed-meshheading:1561804-... | lld:pubmed |
| pubmed-article:1561804 | pubmed:meshHeading | pubmed-meshheading:1561804-... | lld:pubmed |
| pubmed-article:1561804 | pubmed:meshHeading | pubmed-meshheading:1561804-... | lld:pubmed |
| pubmed-article:1561804 | pubmed:meshHeading | pubmed-meshheading:1561804-... | lld:pubmed |
| pubmed-article:1561804 | pubmed:meshHeading | pubmed-meshheading:1561804-... | lld:pubmed |
| pubmed-article:1561804 | pubmed:meshHeading | pubmed-meshheading:1561804-... | lld:pubmed |
| pubmed-article:1561804 | pubmed:meshHeading | pubmed-meshheading:1561804-... | lld:pubmed |
| pubmed-article:1561804 | pubmed:meshHeading | pubmed-meshheading:1561804-... | lld:pubmed |
| pubmed-article:1561804 | pubmed:articleTitle | In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion. | lld:pubmed |
| pubmed-article:1561804 | pubmed:affiliation | Department of Surgery, Jules Bordet Institute, Université Libre de Bruxelles, Belgium. | lld:pubmed |
| pubmed-article:1561804 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1561804 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1561804 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1561804 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1561804 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1561804 | lld:pubmed |
